400 related articles for article (PubMed ID: 24567198)
21. Surgical management of BRCA-mutation carriers: A single institution experience.
Gentile D; Losurdo A; Sagona A; Zuradelli M; Gatzemeier W; Barbieri E; Testori A; Errico V; Bianchi P; Biondi E; Torrisi R; Santoro A; Tinterri C
Eur J Surg Oncol; 2022 Aug; 48(8):1706-1712. PubMed ID: 35534308
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
Li X; You R; Wang X; Liu C; Xu Z; Zhou J; Yu B; Xu T; Cai H; Zou Q
Clin Cancer Res; 2016 Aug; 22(15):3971-81. PubMed ID: 26979395
[TBL] [Abstract][Full Text] [Related]
23. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
24. Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
Chiba A; Hoskin TL; Hallberg EJ; Cogswell JA; Heins CN; Couch FJ; Boughey JC
Ann Surg Oncol; 2016 Oct; 23(10):3232-8. PubMed ID: 27338744
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.
Evron E; Ben-David AM; Goldberg H; Fried G; Kaufman B; Catane R; Pfeffer MR; Geffen DB; Chernobelsky P; Karni T; Abdah-Bortnyak R; Rosengarten O; Matceyevsky D; Inbar M; Kuten A; Corn BW
Ann Oncol; 2019 Mar; 30(3):412-417. PubMed ID: 30475942
[TBL] [Abstract][Full Text] [Related]
26. Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer.
Park S; Lee JE; Ryu JM; Kim I; Bae SY; Lee SK; Yu J; Kim SW; Nam SJ
World J Surg; 2018 May; 42(5):1384-1390. PubMed ID: 29147896
[TBL] [Abstract][Full Text] [Related]
27. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.
Nemati Shafaee M; Goutsouliak K; Lin H; Bevers TB; Gutierrez-Barrera A; Bondy M; Arun B
Breast Cancer Res Treat; 2022 Nov; 196(1):143-152. PubMed ID: 36006499
[TBL] [Abstract][Full Text] [Related]
28. Preoperative genetic testing affects surgical decision making in breast cancer patients.
Lokich E; Stuckey A; Raker C; Wilbur JS; Laprise J; Gass J
Gynecol Oncol; 2014 Aug; 134(2):326-30. PubMed ID: 24910453
[TBL] [Abstract][Full Text] [Related]
29. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
30. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Gershman S; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; McLennan J; Eisen A; Foulkes WD; Rosen B; Sun P; Narod SA
Br J Cancer; 2011 Apr; 104(9):1384-92. PubMed ID: 21487411
[TBL] [Abstract][Full Text] [Related]
31. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
[TBL] [Abstract][Full Text] [Related]
32. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
Ludwig KK; Neuner J; Butler A; Geurts JL; Kong AL
Am J Surg; 2016 Oct; 212(4):660-669. PubMed ID: 27649974
[TBL] [Abstract][Full Text] [Related]
33. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
[TBL] [Abstract][Full Text] [Related]
34. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
35. BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for
Sun J; Chu F; Pan J; Zhang Y; Yao L; Chen J; Hu L; Zhang J; Xu Y; Wang X; Cao W; Xie Y
J Clin Oncol; 2023 Feb; 41(5):991-999. PubMed ID: 36480783
[TBL] [Abstract][Full Text] [Related]
36. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
37. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
38. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C
Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859
[TBL] [Abstract][Full Text] [Related]
39. BRCA mutation testing in determining breast cancer therapy.
Smith KL; Isaacs C
Cancer J; 2011; 17(6):492-9. PubMed ID: 22157293
[TBL] [Abstract][Full Text] [Related]
40. Numerous high-risk epithelial lesions in familial breast cancer.
Hoogerbrugge N; Bult P; Bonenkamp JJ; Ligtenberg MJ; Kiemeney LA; de Hullu JA; Boetes C; Niermeijer MF; Brunner HG
Eur J Cancer; 2006 Oct; 42(15):2492-8. PubMed ID: 16908132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
